Heidi Egloff1, Aminah Jatoi2. 1. a Department of Medicine , Mayo Clinic , Rochester , Minnesota , USA. 2. b Department of Oncology , Mayo Clinic , Rochester , Minnesota , USA.
Abstract
OBJECTIVE: Few studies have examined toxicity from potentially curative chemotherapy in ovarian cancer patients at risk for breast cancer susceptibility (BRCA) mutation. METHODS/ RESULTS: Ninety-four of the 482 patients appeared at risk for a mutation based on family history and 23 had a confirmed mutation. Hospitalization or emergency department visits were not increased based on family history with odds ratios (95% confidence intervals) of 0.88 (0.52, 1.45) (p =.62) and 0.90 (0.49, 1.58) (p =.71), respectively; similar findings were observed with confirmed mutations. Trends favored improved survival. CONCLUSIONS: Concern for a BRCA mutation should not preclude full dose chemotherapy in ovarian cancer patients treated with curative intent.
OBJECTIVE: Few studies have examined toxicity from potentially curative chemotherapy in ovarian cancerpatients at risk for breast cancer susceptibility (BRCA) mutation. METHODS/ RESULTS: Ninety-four of the 482 patients appeared at risk for a mutation based on family history and 23 had a confirmed mutation. Hospitalization or emergency department visits were not increased based on family history with odds ratios (95% confidence intervals) of 0.88 (0.52, 1.45) (p =.62) and 0.90 (0.49, 1.58) (p =.71), respectively; similar findings were observed with confirmed mutations. Trends favored improved survival. CONCLUSIONS: Concern for a BRCA mutation should not preclude full dose chemotherapy in ovarian cancerpatients treated with curative intent.
Authors: Andrew Garcia; Corey Frahm; Joanne M Jeter; Ivo Abraham; Setsuko K Chambers; Janiel M Cragun; Ali McBride Journal: J Adv Pract Oncol Date: 2019-07-01